This article is part of the supplement: 25th International Symposium on Intensive Care and Emergency Medicine
Evolution of resistance in Acinetobacter baumannii in a Tunisian intensive care unit after antibiotherapy restriction
CAMU, Tunis, Tunisia
Critical Care 2005, 9(Suppl 1):P19 doi:10.1186/cc3082
The electronic version of this article is the complete one and can be found online at:
| Published: | 7 March 2005 |
© 2005 BioMed Central Ltd
Introduction
The prevalence of carbapenem-resistant isolates of Acinetobacter baumannii is increasing in Tunisian ICUs. The wide use of antibiotherapy is implicated certainly in this mechanism of resistance.
Objective
The purpose of this study is to evaluate the evolution of A. baumannii resistance after a new strategy of prescription consisting of controlling and restriction of antibiotherapy prescription.
Materials and methods
Evolution of resistance of all A. baumannii isolates is compared between 2001 (before antibiotherapy restriction) and 2003–2004 (after).
Results
See Table 1.
Conclusion
With antibiotherapy restriction we have obtained a significant reduction of resistance for piperacillin, ceftazidim and amikacin. We have obtained also a decrease of carbapenem-resistant isolates (37% vs 25%) but not significant enough if compared with other countries (5% in New York and 11% in Brazil).